FindTrial
Sign In

Assessment of memory cells response to Mycobacterium Indicus Pranii vaccination

Assessment of innate memory NK cells in response to Mycobacterium Indicus Pranii vaccination as a part of a national clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028326
Enrollment
40
Registered
2020-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Mycobacterium Indicus Pranii (MIP) Vaccine : 0.3 ml intradermal on either deltoid for three days in critically ill subjects with COVID-19 disease Intervention2: Mycobacterium Indicus Pr

Sponsors

Manashi Chakrabarti Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. COVID positive (by RT-PCR method) patients who are critically ill (room air SPO2 25), and health care workers and close contacts. 2. Signed informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Age-less than 20 years or greater than 80 years 3. Those with HIV infection, chronic kidney disease, chronic liver disease, hematological malignancy, and those on immunosuppressive drugs 4. Those who have received hydroxychloroquine for COVID-19

Design outcomes

Primary

MeasureTime frame
To evaluate the innate memory NK cell in response to MIP vaccine.Timepoint: At day 0 and week 4—

Secondary

MeasureTime frame
To determine any relation between vaccine dose and schedule and the response.Timepoint: Till end of study—

Countries

India

Contacts

Public ContactDr Jyoti Rastogi

Dharamshila Narayana Superspeciality Hospital

bmt.dnsh@narayanahealth.org09811166314

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026